On December 29, 2025, the 8th Investment Annual Conference, guided by the Shanghai United Media Group and hosted by CLS, was grandly held in Hefei, Anhui. The site unveiled the “2025 Most Influential and Valuable Companies in the Capital Market” list. As an authoritative selection renowned for its significant brand influence and professional credibility within China’s financial and economic sector, this event has been successfully held for eight consecutive years. It aims to recognize outstanding enterprises that demonstrate forward-looking strategic vision, robust development potential, and exceptional performance in the capital market.
Vigonvita has been honored with the 2025 “Most Investable Company Award” for its profound technological expertise, sustained innovation capabilities, and outstanding performance in the capital market within the biopharmaceutical field. This accolade serves as strong validation of the company’s continuous innovation capabilities and development potential. Furthermore, it represents full recognition from the capital market for its persistent creation of value in biopharmaceutical subsectors, steadfast commitment to delivering returns for investors, and leadership in driving high-quality industry development.
Looking ahead, Vigonvita will further strengthen communication with global investors, continuously increase R&D investment, and enhance corporate profitability and innovation conversion efficiency. The company is dedicated to delivering multi-dimensional value to reciprocate the trust and support of its investors and to contribute to the innovative development of the biopharmaceutical industry.